Afsaneh Barzi

10PUBLICATIONS
44CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)ChemotherapyMolecular targetsGene expression (incl. microarray and other genome-wide approaches)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Apr 23, 2025
Cost-effectiveness analysis of regorafenib dose optimization for refractory metastatic colorectal cancer.

Tanios Bekaii-Saab, Sang Kyu Cho, Brian Hocum

|Oct 30, 2024
Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial.

Daniel H Ahn, Maya Ridinger, Timothy L Cannon

|Sep 12, 2024
Safety of pressurized intraperitoneal aerosolized chemotherapy in biliary cancer patients with peritoneal metastases.

Daneng Li, Christiana Crook, Vincent Chung

|Jan 17, 2024
Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study.

Daniel H Ahn, Afsaneh Barzi, Maya Ridinger

|Mar 27, 2023
A Phase II Study Investigating Cabozantinib in Patients with Refractory Metastatic Colorectal Cancer (AGICC 17CRC01).

Aaron J Scott, Atrayee Basu Mallick, Efrat Dotan

|Dec 03, 2021
Novel Program Offering Remote, Asynchronous Subspecialist Input in Thoracic Oncology: Early Experience and Insights Gained During the COVID-19 Pandemic.

Howard Jack West, Yuan Angela Tan, Afsaneh Barzi

Pageof 2

Frequent Collaborators

4 joint publications

Heinz-Josef Lenz

2 joint publications

Ramanand A Subramanian

2 joint publications

Errin Samuëlsz

2 joint publications

Peter J P Croucher